Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Protara Therapeutics (Nasdaq: TARA) said management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:45 pm PT in San Francisco.
A live webcast will be available via the company’s Events and Presentations page at https://ir.protaratx.com and the webcast will be archived for a limited time after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TARA gained 11.13%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.5% during that session. Our momentum scanner triggered 36 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $30M to the company's valuation, bringing the market cap to $303M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TARA fell 5.01% while peers showed mixed moves: most (e.g., EQ -18.87%, KALA -1.72%, BMEA -1.56%) were down, but IOBT rose 5.69%. Only KALA appeared in the momentum scanner, also moving down.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Regulatory designations | Positive | +0.2% | Multiple FDA designations for TARA-002 in pediatric lymphatic malformations. |
| Dec 08 | Equity offering close | Positive | +0.3% | Closing of $75M underwritten public offering to fund clinical programs. |
| Dec 04 | Equity offering pricing | Positive | +0.7% | Pricing of $75M offering at $5.75 per share with underwriters’ option. |
| Dec 04 | Equity offering launch | Positive | +0.7% | Announcement of proposed $75M public offering under existing shelf. |
| Dec 03 | Clinical data update | Positive | +9.3% | Updated Phase 2 ADVANCED-2 data with high CR rates and FDA feedback. |
Recent clinical and financing announcements generally saw positive price reactions, suggesting investors have been receptive to both data updates and capital-raising.
Over the past two months, TARA has combined clinical progress with balance sheet strengthening. On Dec 3, 2025, updated Phase 2 ADVANCED-2 data in NMIBC with strong complete response rates led to a 9.32% gain. In early December, a series of public offering announcements totaling about $75 million–$86.3 million all saw modestly positive price reactions. Most recently, on Jan 5, 2026, multiple FDA designations for TARA-002 in pediatric lymphatic malformations produced a small positive move. Today’s conference appearance fits into this ongoing visibility and development narrative.
Market Pulse Summary
The stock surged +11.1% in the session following this news. A strong positive reaction aligns with the pattern of investors rewarding visibility events and clinical milestones, as seen after prior TARA-002 data and FDA designations. Participation in a major healthcare conference can increase institutional awareness and reinforce the recent clinical and financing progress. However, past equity offerings and the pre-revenue status suggest that enthusiasm could moderate as investors refocus on execution risks, trial timelines, and future capital needs.
AI-generated analysis. Not financial advice.
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco.
A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When will Protara Therapeutics (TARA) present at the 44th Annual J.P. Morgan Healthcare Conference?
How can investors watch the Protara (TARA) presentation on January 14, 2026?
Will the Protara (TARA) J.P. Morgan webcast be available after the live presentation?
What is the ticker symbol for Protara Therapeutics presenting at the J.P. Morgan conference?
Where is the 44th Annual J.P. Morgan Healthcare Conference presentation location for Protara (TARA)?
